Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Min‐Sik Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7317-5360; OpenAlex author ID A5064143823. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 7 papers

Papers 12

  1. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Co-author DOI 10.1038/s43018-022-00479-7↗
  2. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtype… Co-author DOI 10.1038/s43018-023-00581-4↗
  3. Whole exome sequencing and RNA sequencing analyses of PDAC samples Co-author DOI 10.21203/rs.3.pex-2062/v1↗
  4. Mass spectrometry-based proteomic analysis of PDAC samples Co-author DOI 10.21203/rs.3.pex-2063/v1↗
  5. Bioinformatics analysis of PDAC subtypes Co-author DOI 10.21203/rs.3.pex-2064/v1↗
  6. Cell-based assays for potential prognostic biomarkers in PDAC Co-author DOI 10.21203/rs.3.pex-2065/v1↗
  7. Assays for orthotopic PDAC mouse models Co-author DOI 10.21203/rs.3.pex-2066/v1↗
  8. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers13143404↗
  9. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. First author DOI 10.1158/2326-6066.cir-15-0200-t↗
  10. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Co-author DOI 10.1074/mcp.m114.038547↗
  11. Pancreatic Cancer Database: an integrative resource for pancreatic cancer. First author DOI 10.4161/cbt.29188↗
  12. Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). Co-author DOI 10.1021/pr300483r↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sangyeop Hyun · 7 shared papers, 2023 · strength 0.83
  2. Sung Hee Baek · 7 shared papers, 2023 · strength 0.83
  3. Hongbeom Kim · 7 shared papers, 2023 · strength 0.83
  4. Keehoon Jung · 7 shared papers, 2023 · strength 0.83
  5. Sang‐Won Lee · 7 shared papers, 2023 · strength 0.83
  6. Do Young Hyeon · 7 shared papers, 2023 · strength 0.83
  7. Ja‐Lok Ku · 7 shared papers, 2023 · strength 0.83
  8. Duk Ki Kim · 7 shared papers, 2023 · strength 0.83
  9. Taesung Park · 7 shared papers, 2023 · strength 0.83
  10. Gibeom Kim · 7 shared papers, 2023 · strength 0.83
  11. Daechan Park · 7 shared papers, 2023 · strength 0.83
  12. Wooil Kwon · 7 shared papers, 2023 · strength 0.83
  13. Jin‐Young Jang · 5 shared papers, 2023 · strength 0.59
  14. Akhilesh Pandey · 5 shared papers, 2012–2021 · strength 0.26
  15. Jin‐Young Jang · 2 shared papers, 2023 · strength 0.24
  16. Vijay Sagar Madamsetty · 1 shared paper, 2021 · strength 0.11
  17. Santosh Renuse · 1 shared paper, 2021 · strength 0.11
  18. Rondell Patrell Graham · 1 shared paper, 2021 · strength 0.11
  19. Mark Joseph Truty · 1 shared paper, 2021 · strength 0.11
  20. Valery G. Krasnoperov · 1 shared paper, 2021 · strength 0.11
  21. Debabrata Mukhopadhyay · 1 shared paper, 2021 · strength 0.11
  22. Anirban Maitra · 3 shared papers, 2012–2014 · strength 0.09
  23. Ralph H. Hruban MD · 3 shared papers, 2012–2014 · strength 0.09
  24. Elizabeth M. Jaffee · 2 shared papers, 2012–2016 · strength 0.08
  25. Christine A. Iacobuzio–Donahue · 2 shared papers, 2012–2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.